No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
New Indication Alert: J&J Applies for Expanded US and EU Indications of Darzalex® Quadruplet Regimen for Multiple Myeloma
On 10 October 2024, Johnson & Johnson (J&J) announced that it submitted a Type II variation application to the EMA seeking an indication extension for Darzalex® (daratumumab) subcutaneous formulation in combination with bortezomib, lenalidomide and...